News|Articles|November 18, 2026

The Practice Brief: iPLEDGE Changes, Medicare Cuts, and Smarter Care

NP/PA Connect
Listen
0:00 / 0:00

Key Takeaways

  • iPLEDGE REMS updates permit some home follow-up pregnancy testing, remove extra waiting after missed pickups, and reduce counseling documentation for non–pregnancy-capable patients, while maintaining core safeguards and certification.
  • Anticipated 2027 Medicare payment reductions and modifier 25-related policy changes may reshape dermatology practice economics, affecting service mix, documentation strategies, staffing, and access to time-sensitive skin cancer care.
SHOW MORE

Stay ahead with a weekly roundup of the biggest practice management, AI, policy, business, and professional development updates in dermatology.

Help your practice thrive—one week at a time.


Welcome to The Practice Brief, your weekly roundup of the news, trends, and ideas shaping the future of dermatology. Each edition highlights the biggest developments in practice management, reimbursement, policy, AI, business, and professional growth, while connecting them to existing Dermatology Times and NP/PA Connect coverage. The goal isn't just to keep you informed—it's to help you discover what's next, identify opportunities, and keep your practice performing at its best.

From updated isotretinoin requirements to reimbursement pressures and treatment optimization, explore the developments shaping dermatology practice

Updated iPLEDGE Requirements Could Ease Isotretinoin Management

New modifications to the FDA's iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) took effect November 15, introducing greater flexibility for isotretinoin prescribing and dispensing. Patients who can become pregnant may now complete certain follow-up pregnancy tests outside medical settings, including at home, after fulfilling initial testing requirements in a medical setting.

The revisions also eliminate additional waiting periods after missed prescription pickup windows and reduce counseling documentation requirements for patients who cannot become pregnant. Although the changes aim to decrease administrative burdens, prescribers must continue following program safeguards, including pregnancy prevention requirements and applicable certification procedures.

▶ Why it matters: For dermatology NPs and PAs prescribing isotretinoin, the updates create an opportunity to streamline patient visits, reduce unnecessary treatment interruptions, and improve access. Practices should review their testing protocols, patient education materials, and dispensing workflows to ensure compliance with the revised requirements.

Medicare Reimbursement Changes Raise Concerns for Dermatology Practices

The American Academy of Dermatology Association (AADA) has warned that dermatologists could face an approximately 6% reduction in Medicare payments in 2027 under the finalized Medicare Physician Fee Schedule.

Although the Centers for Medicare & Medicaid Services (CMS) narrowed its proposed modifier 25 payment reduction, the final policy still reduces reimbursement for certain evaluation and management services performed on the same day as procedures with 0-day global periods. Changes to Medicare conversion factors and practice expense calculations could create additional financial pressures for dermatology practices.

The AADA has cautioned that these reductions may affect access to essential dermatologic services, including timely skin cancer diagnosis and treatment.

▶ Why it matters: Reimbursement changes can influence scheduling, staffing, procedure availability, and practice sustainability. Dermatology teams should evaluate how the 2027 policies may affect their service mix, documentation practices, and financial planning while monitoring additional AADA guidance.

Chronic Hand Eczema Findings Highlight Opportunities for Earlier Recognition

New research highlighted in the November 16 Journal Digest found that 9.6% of 10,636 surveyed US adults reported a health care professional diagnosis of chronic hand eczema. Prevalence exceeded 13% among adults aged 18 to 39 years and was higher among employed and urban populations.

The findings underscore the burden of persistent and recurrent hand dermatitis, particularly among working-age adults who may experience repeated exposure to occupational irritants and allergens.

For dermatology clinicians, distinguishing chronic hand eczema from transient irritation and identifying relevant exposures remain important components of assessment and management.

▶ Why it matters: Chronic hand eczema can interfere with employment, daily activities, and quality of life. NPs and PAs can help identify patients who may benefit from additional evaluation, individualized skin protection strategies, and treatment escalation when conventional approaches are insufficient.

Get Involved With Dermatology Times

For APPs across all stages of their dermatology careers, opportunities to connect, learn, and share experiences can be an important part of professional growth. Dermatology Times invites nurse practitioners and physician assistants to share their perspectives through NP/PA Connect. APPs can contribute clinical insights, career experiences, advocacy efforts, lessons learned, and perspectives on emerging treatments while connecting with colleagues across the dermatology community.

Interested in getting involved? Contact editor Shannon Heaning at sheaning@mjhlifesciences.com to contribute.

Biologic Response Patterns May Help Guide HS Treatment Optimization

A recent cohort study involving 107 patients with hidradenitis suppurativa (HS) explored whether symptom recurrence near the end of a biologic dosing interval could inform treatment adjustments.

Patients experiencing an end-of-dose effect underwent biologic dose intensification, whereas those without this pattern received adjunctive long-term antibiotics. The response-guided approach was associated with improvements across 7 clinical outcomes within 3 to 5 months, with benefits sustained through subsequent follow-up.

Although the nonrandomized design limits conclusions about comparative effectiveness, the findings suggest that the timing of symptom recurrence may provide useful information when evaluating incomplete treatment responses.

▶ Why it matters: When patients report persistent HS symptoms despite biologic therapy, understanding when flares occur may help clinicians distinguish possible waning treatment effects from ongoing inflammatory activity. Documenting symptom patterns can support more individualized treatment discussions, while recognizing that dosing changes require consideration of evidence, labeling, safety, and coverage.

Melanoma Risk Models Reinforce the Need for Clinical Judgment

As dermatology practices increasingly explore risk prediction tools, new findings highlight the importance of evaluating their performance before incorporating them into routine care.

A study assessing 6 melanoma risk prediction models found variable discriminatory performance, with areas under the receiver operating characteristic curve ranging from 0.58 to 0.70. Most models underestimated melanoma risk in the population studied.

The results emphasize that prediction tools may not perform consistently across patient populations and that external validation and recalibration are important before clinical implementation.

▶ Why it matters: Risk prediction tools may eventually help dermatology teams prioritize screening, counseling, and surveillance. However, clinicians should avoid relying on model-generated estimates in isolation. Patient history, clinical examination, established risk factors, and individualized judgment remain essential to melanoma prevention and early detection.

References

  1. Heaning S. FDA implements updated iPLEDGE REMS requirements for isotretinoin. Dermatology Times. Published November 16, 2026.
  2. Heaning S. AADA warns of 6% Medicare payment cut for dermatologists in 2027. Dermatology Times. Published November 5, 2026.
  3. Heaning S. Journal Digest: November 16. Dermatology Times. Published November 16, 2026.

Dermatology Times NP/PA Connect | The Practice Brief


Related to this article

Journal Digest: November 16
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.